Arcturus Therapeutics Stock Forecast, Price & News

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arcturus Therapeutics in the last year. There are currently 6 sell ratings, 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Arcturus Therapeutics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ARCT, but not buy additional shares or sell existing shares.
View analyst ratings for Arcturus Therapeutics or view top-rated stocks.

Wall Street analysts have given Arcturus Therapeutics a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Arcturus Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Arcturus Therapeutics saw a drop in short interest during the month of August. As of August 13th, there was short interest totaling 2,260,000 shares, a drop of 38.6% from the July 29th total of 3,680,000 shares. Based on an average daily volume of 863,700 shares, the days-to-cover ratio is presently 2.6 days. Currently, 10.5% of the shares of the company are short sold.
View Arcturus Therapeutics' Short Interest.

Arcturus Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, November 8th 2021.
View our earnings forecast for Arcturus Therapeutics.

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) released its earnings results on Sunday, August, 8th. The biotechnology company reported ($2.07) EPS for the quarter, missing analysts' consensus estimates of ($1.99) by $0.08. Arcturus Therapeutics had a negative net margin of 1,874.18% and a negative trailing twelve-month return on equity of 48.39%.
View Arcturus Therapeutics' earnings history.

Arcturus Therapeutics' stock was trading at $13.09 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ARCT shares have increased by 310.8% and is now trading at $53.78.
View which stocks have been most impacted by COVID-19.

10 analysts have issued 1-year price objectives for Arcturus Therapeutics' shares. Their forecasts range from $23.00 to $133.00. On average, they expect Arcturus Therapeutics' stock price to reach $63.55 in the next year. This suggests a possible upside of 18.2% from the stock's current price.
View analysts' price targets for Arcturus Therapeutics or view top-rated stocks among Wall Street analysts.

9 employees have rated Arcturus Therapeutics CEO Joe Payne on Glassdoor.com. Joe Payne has an approval rating of 90% among Arcturus Therapeutics' employees.

Some companies that are related to Arcturus Therapeutics include Cerevel Therapeutics (CERE), I-Mab (IMAB), Ionis Pharmaceuticals (IONS), Alkermes (ALKS), Arvinas (ARVN), TG Therapeutics (TGTX), Schrödinger (SDGR), Hypera (HYPMY), Reata Pharmaceuticals (RETA), Turning Point Therapeutics (TPTX), Arena Pharmaceuticals (ARNA), Galapagos (GLPG), Karuna Therapeutics (KRTX), Verve Therapeutics (VERV) and Prothena (PRTA).
View all of ARCT's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Arcturus Therapeutics investors own include Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Novavax (NVAX), Dynavax Technologies (DVAX), Pfizer (PFE), OPKO Health (OPK), NVIDIA (NVDA), Abbott Laboratories (ABT), CRISPR Therapeutics (CRSP) and (SNY).

Arcturus Therapeutics trades on the NASDAQ under the ticker symbol "ARCT."

Arcturus Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include Federated Hermes Inc. (11.50%), ARK Investment Management LLC (10.96%), State Street Corp (6.67%), BlackRock Inc. (6.47%), Sumitomo Mitsui Trust Holdings Inc. (4.62%) and Nikko Asset Management Americas Inc. (4.62%). Company insiders that own Arcturus Therapeutics stock include Andy Sassine, Joseph E Payne, Keith C Kummerfeld, Pad Chivukula and Ultragenyx Pharmaceutical Inc.
View institutional ownership trends for Arcturus Therapeutics.

ARCT stock was sold by a variety of institutional investors in the last quarter, including ARK Investment Management LLC, Federated Hermes Inc., Millennium Management LLC, Goldman Sachs Group Inc., Renaissance Technologies LLC, Price T Rowe Associates Inc. MD, Group One Trading L.P., and BlackRock Inc.. Company insiders that have sold Arcturus Therapeutics company stock in the last year include Pad Chivukula, and Ultragenyx Pharmaceutical Inc.
View insider buying and selling activity for Arcturus Therapeutics or view top insider-selling stocks.

ARCT stock was purchased by a variety of institutional investors in the last quarter, including Nikko Asset Management Americas Inc., Sumitomo Mitsui Trust Holdings Inc., State Street Corp, Morgan Stanley, Morgan Stanley, Nuveen Asset Management LLC, Rafferty Asset Management LLC, and Monashee Investment Management LLC. Company insiders that have bought Arcturus Therapeutics stock in the last two years include Andy Sassine, Joseph E Payne, and Keith C Kummerfeld.
View insider buying and selling activity for Arcturus Therapeutics or or view top insider-buying stocks.

Shares of ARCT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ARCT stock can currently be purchased for approximately $53.78.

Arcturus Therapeutics has a market capitalization of $1.42 billion and generates $9.54 million in revenue each year. The biotechnology company earns $-72,150,000.00 in net income (profit) each year or ($3.55) on an earnings per share basis.

Arcturus Therapeutics employs 118 workers across the globe.

The official website for Arcturus Therapeutics is www.arcturusrx.com.

Arcturus Therapeutics is headquartered at 10628 SCIENCE CENTER DRIVE SUITE 200, SAN DIEGO CA, 92121.

Arcturus Therapeutics' mailing address is 10628 SCIENCE CENTER DRIVE SUITE 200, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at (858) 900-2660 or via email at [email protected]